Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter Study of Erlotinib (Tarceva®) as First Line Therapy Until and Beyond RECIST Progression in NSCLC Patients Who Harbour EGFR Mutations

NCT01310036 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01310036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01310036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter Study of Erlotinib (Tarceva®) as First Line Therapy Until and Beyond RECIST Progression in NSCLC Patients Who Harbour EGFR Mutations
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
December 30, 2016
Enrollment
208 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer